<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550443</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-006</org_study_id>
    <nct_id>NCT03550443</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study</brief_title>
  <official_title>RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of multiple oral doses of RTA 402
      (5, 10, or 15 mg) administered once daily in patients with diabetic kidney disease (DKD)
      using the time to onset of a ≥ 30% decrease in estimated glomerular filtration rate
      calculated from serum creatinine (eGFR) from baseline or end-stage renal disease (ESRD) as an
      indicator in a randomized, double-blind, placebo-controlled study; the safety of RTA 402 will
      also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of a ≥ 30% decrease in eGFR from baseline or ESRD</measure>
    <time_frame>Through study completion, approximately 2 to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of a ≥ 40% decrease in eGFR from baseline or ESRD</measure>
    <time_frame>Through study completion, approximately 2 to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of a ≥ 53% decrease in eGFR from baseline or ESRD</measure>
    <time_frame>Through study completion, approximately 2 to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of ESRD</measure>
    <time_frame>Through study completion, approximately 2 to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR from baseline at each evaluation time point</measure>
    <time_frame>Through study completion, approximately 2 to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1323</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>RTA 402(Bardoxolone methyl)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl 5 mg capsules</description>
    <arm_group_label>RTA 402(Bardoxolone methyl)</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing an inert placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with DKD

          -  Mean eGFR ≥ 15 and &lt; 60 mL/min/1.73 m²

          -  Albumin/creatinine ratio (ACR) ≤ 3500 mg/g Cr

          -  Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin
             II receptor blocker (ARB) with no change in dosage or medication etc.

        Exclusion Criteria:

          -  Diabetes mellitus that is neither type 1 nor type 2

          -  Decreased renal function mainly attributed to a non-diabetic cause

          -  History of renal transplantation or upcoming preemptive renal transplantation

          -  Confirmed mean systolic blood pressure &gt; 160 mmHg or a confirmed mean diastolic blood
             pressure &gt; 90 mmHg during the 8-week period before screening

          -  Hemoglobin A1c level &gt; 10.0% during screening

          -  Serum albumin level ≤ 3.0 g/dL during screening

          -  Cardiovascular disease specified in the study protocol

          -  History of cardiac failure

          -  BNP level &gt; 200 pg/mL during screening etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Japan Community Health care Organization Sendai Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>981-0912</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bardoxolone Methyl</keyword>
  <keyword>Diabetic Kidney Disease</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Kidney Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

